AR076070A1 - Absorbente de fosfato para el tratamiento de la hiperfosfatemia - Google Patents
Absorbente de fosfato para el tratamiento de la hiperfosfatemiaInfo
- Publication number
- AR076070A1 AR076070A1 ARP100100600A ARP100100600A AR076070A1 AR 076070 A1 AR076070 A1 AR 076070A1 AR P100100600 A ARP100100600 A AR P100100600A AR P100100600 A ARP100100600 A AR P100100600A AR 076070 A1 AR076070 A1 AR 076070A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition according
- iron
- treatment
- magnesium
- calcium
- Prior art date
Links
- 229910019142 PO4 Inorganic materials 0.000 title abstract 3
- 201000005991 hyperphosphatemia Diseases 0.000 title abstract 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title abstract 3
- 239000010452 phosphate Substances 0.000 title abstract 3
- 230000002745 absorbent Effects 0.000 title 1
- 239000002250 absorbent Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 4
- 229910052791 calcium Inorganic materials 0.000 abstract 4
- 239000011575 calcium Substances 0.000 abstract 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 3
- 208000020832 chronic kidney disease Diseases 0.000 abstract 3
- 159000000014 iron salts Chemical class 0.000 abstract 3
- 229910052749 magnesium Inorganic materials 0.000 abstract 3
- 239000011777 magnesium Substances 0.000 abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 235000010216 calcium carbonate Nutrition 0.000 abstract 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 abstract 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract 2
- 238000001631 haemodialysis Methods 0.000 abstract 2
- 230000000322 hemodialysis Effects 0.000 abstract 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 2
- 239000001095 magnesium carbonate Substances 0.000 abstract 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 abstract 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 abstract 1
- 108010024636 Glutathione Proteins 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- CUPCBVUMRUSXIU-UHFFFAOYSA-N [Fe].OOO Chemical compound [Fe].OOO CUPCBVUMRUSXIU-UHFFFAOYSA-N 0.000 abstract 1
- 150000001242 acetic acid derivatives Chemical class 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 abstract 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 235000014633 carbohydrates Nutrition 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- MSNWSDPPULHLDL-UHFFFAOYSA-K ferric hydroxide Chemical compound [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 abstract 1
- 239000007941 film coated tablet Substances 0.000 abstract 1
- 229930003944 flavone Natural products 0.000 abstract 1
- 150000002213 flavones Chemical class 0.000 abstract 1
- 235000011949 flavones Nutrition 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 229960003180 glutathione Drugs 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 239000004021 humic acid Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 150000004679 hydroxides Chemical class 0.000 abstract 1
- 150000002505 iron Chemical class 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 150000002506 iron compounds Chemical class 0.000 abstract 1
- 235000014413 iron hydroxide Nutrition 0.000 abstract 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical class [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 abstract 1
- 229910021519 iron(III) oxide-hydroxide Inorganic materials 0.000 abstract 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 abstract 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 abstract 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 abstract 1
- 239000002370 magnesium bicarbonate Substances 0.000 abstract 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 abstract 1
- 235000014380 magnesium carbonate Nutrition 0.000 abstract 1
- 239000000347 magnesium hydroxide Substances 0.000 abstract 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 abstract 1
- 159000000003 magnesium salts Chemical class 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- -1 oxides Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
- 229940046008 vitamin d Drugs 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Constituyen objeto de la presente solicitud composiciones que comprenden una mezcla de sales de calcio, magnesio y hierro usadas como preparacion farmacéutica para la absorcion de fosfato, especialmente usadas como preparaciones farmacéuticas para el tratamiento de la hiperfosfatemia, la enfermedad renal cronica así como para el tratamiento de pacientes de hemodiálisis. Reivindicacion 2: Una composicion de conformidad con la reivindicacion 1, la cual comprende la absorcion de fosfato en el cuerpo y/o de los fluidos corporales, o bien interna o externamente. Reivindicacion 3: Una composicion de conformidad con las reivindicaciones 1 o 2, la cual comprende el tratamiento de hiperfosfatemia, para el tratamiento de pacientes de enfermedad renal cronica (CKD) y/o para el tratamiento de pacientes de hemodiálisis. Reivindicacion 4: Una composicion de conformidad con cualquiera de las reivindicaciones anteriores, donde las sales de calcio y magnesio se seleccionan del grupo que consiste en carbonatos, carbonatos de hidrogeno, carbonatos básicos, acetatos, oxidos, hidroxidos y mezclas de los mismos. Reivindicacion 5: Una composicion de conformidad con cualquiera de las reivindicaciones anteriores, donde se selecciona la sal de hierro del grupo que consiste en oxido de hierro, hidroxido de hierro, oxihidroxido de hierro, compuestos complejos de hierro y mezclas de los mismos. Reivindicacion 8: Una composicion de conformidad con cualquiera de las reivindicaciones anteriores, donde las sales de hierro se estabilizan mediante carbohidratos y/o ácido humico. Reivindicacion 17: Una composicion de conformidad con cualquiera de las reivindicaciones anteriores para la administracion de una mezcla de sales de calcio, magnesio y hierro en una cantidad total con base en el metal de Calcio: 80 mg-2400 mg, correspondiente a 2-60 mmol, Magnesio: 49 mg-729 mg, correspondiente a 2-30 mmol, Hierro: 112 mg-1676 mg, correspondiente a 2-30 mmol por dosis diaria. Reivindicacion 21: Una composicion de conformidad con cualquiera de las reivindicaciones anteriores la cual comprende una mezcla de: carbonato de calcio y/o carbonato de hidrogeno de calcio, carbonato de magnesio, carbonato de hidrogeno de magnesio y/o carbonato de magnesio básico e hidroxido de hierro (III) y/o oxihidroxido de hierro (III) y/o oxidos de hierro (III) y/o formas estabilizadas de las mismas. Reivindicacion 26: Una composicion de conformidad con cualquiera de las reivindicaciones anteriores, la cual contiene como mínimo una sustancia activa farmacéuticamente y/o un excipiente aceptable farmacéuticamente. Reivindicacion 27: Una composicion de conformidad con la reivindicacion 26, la cual contiene como mínimo vitamina una sustancia adicional activa farmacéuticamente escogida entre vitamina D y sus derivados, antioxidantes, como vitamina E y/o sus derivados, aminoácidos, como por ejemplo cisteína, péptidos como por ejemplo glutation, flavonas y/o flavonoides o mezclas de los mismos. Reivindicacion 29: Una composicion de conformidad con una de las realizaciones previas la cual está en forma de polvo, gránulos, cápsulas, tabletas, tabletas con cubierta pelicular, barras o sobrecitos. Reivindicacion 30: Una composicion de conformidad con cualquiera de las reivindicaciones anteriores la cual está dirigida al tratamiento de seres humanos. Reivindicacion 32: Una composicion de conformidad con cualquiera de las reivindicaciones anteriores la cual es de administracion oral.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09154107 | 2009-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076070A1 true AR076070A1 (es) | 2011-05-18 |
Family
ID=40627528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100600A AR076070A1 (es) | 2009-03-02 | 2010-03-01 | Absorbente de fosfato para el tratamiento de la hiperfosfatemia |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20120052135A1 (es) |
| EP (1) | EP2403506A1 (es) |
| JP (1) | JP2012519201A (es) |
| KR (1) | KR101497003B1 (es) |
| CN (1) | CN102341111A (es) |
| AR (1) | AR076070A1 (es) |
| AU (1) | AU2010220396B2 (es) |
| BR (1) | BRPI1009110A2 (es) |
| CA (1) | CA2753364A1 (es) |
| CL (1) | CL2011002130A1 (es) |
| IL (1) | IL214509A0 (es) |
| MX (1) | MX2011009144A (es) |
| MY (1) | MY162484A (es) |
| NZ (1) | NZ594730A (es) |
| PE (1) | PE20120327A1 (es) |
| RU (1) | RU2527682C2 (es) |
| SG (1) | SG173887A1 (es) |
| TW (1) | TWI454267B (es) |
| WO (1) | WO2010100112A1 (es) |
| ZA (1) | ZA201106305B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0913525D0 (en) * | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
| EP2548562A1 (de) | 2011-07-18 | 2013-01-23 | SeBo GmbH | Kombinationstherapie mit Eisen-basierenden Phosphatadsorbern |
| JP6417339B2 (ja) * | 2013-03-08 | 2018-11-07 | ヴィダシム・インコーポレーテッド | 金属イオン−機能性繊維成分錯体組成物、その調製および使用 |
| EP2805603B1 (de) * | 2013-05-22 | 2017-01-11 | CLAAS E-Systems KGaA mbH & Co KG | Vorrichtung und Verfahren zur Überwachung der Schneidenschärfe |
| WO2015181205A1 (en) | 2014-05-28 | 2015-12-03 | Biaqua B.V. | Method for removing phosphate from water fractions |
| CN105232767A (zh) * | 2015-09-29 | 2016-01-13 | 江苏锦宇环境工程有限公司 | 一种制备吸附磷酸盐的药物制剂的方法 |
| CN107397760B (zh) * | 2016-05-19 | 2021-07-30 | 欣凯医药化工中间体（上海）有限公司 | 基于铁的氢氧化物－低分子量糖的磷结合剂、其制备方法及其应用 |
| CN107397758A (zh) * | 2016-05-19 | 2017-11-28 | 欣凯医药化工中间体（上海）有限公司 | 一种磷结合剂及其制备方法 |
| WO2018222865A1 (en) * | 2017-05-31 | 2018-12-06 | Mars, Incorporated | Methods of diagnosing and treating chronic kidney disease |
| CN119488480A (zh) | 2019-02-28 | 2025-02-21 | 雷尼布斯治疗公司 | 新型铁组合物及其制造和使用方法 |
| US20210130251A1 (en) * | 2019-07-17 | 2021-05-06 | Water Warriors Inc. | Adsorbent Structures for the Removal of Phosphates and Ammonia from Wastewater and Methods of Use |
| MX2021015590A (es) * | 2019-07-23 | 2022-03-02 | Nestle Sa | Metodos y composiciones con beneficios renales para felinos. |
| CN113029978A (zh) * | 2019-12-25 | 2021-06-25 | 远大生命科学(辽宁)有限公司 | 一种检测含镧试剂的磷结合能力的方法 |
| CN111905736B (zh) * | 2020-07-23 | 2021-10-26 | 安徽工业大学 | 一种半胱氨酸功能化改性的羟基氧化铁、电催化剂、制备方法及应用 |
| WO2025176793A1 (en) * | 2024-02-21 | 2025-08-28 | Mars, Incorporated | Food composition for treating mineral bone disorder |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970079A (en) * | 1989-06-05 | 1990-11-13 | Purdue Research Foundation | Method and composition of oxy-iron compounds for treatment of hyperphosphatemia |
| DE19547356A1 (de) * | 1995-12-19 | 1997-06-26 | Vifor Int Ag | Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung |
| GB9720061D0 (en) * | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| DE19917705C1 (de) * | 1999-04-20 | 2000-12-28 | Vitasyn Gmbh | Mittel zur Therapie von Hyperphosphatämie |
| DE102004031181A1 (de) * | 2004-06-28 | 2006-01-19 | Vifor (International) Ag | Phosphatadsorbens |
| MY157620A (en) * | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
| EP1932808A1 (en) * | 2006-12-14 | 2008-06-18 | Novartis AG | Iron(III)-Carbohydrate based phosphate adsorbent |
-
2010
- 2010-03-01 CA CA2753364A patent/CA2753364A1/en not_active Abandoned
- 2010-03-01 EP EP10705883A patent/EP2403506A1/en not_active Withdrawn
- 2010-03-01 BR BRPI1009110A patent/BRPI1009110A2/pt not_active IP Right Cessation
- 2010-03-01 NZ NZ594730A patent/NZ594730A/xx not_active IP Right Cessation
- 2010-03-01 MX MX2011009144A patent/MX2011009144A/es unknown
- 2010-03-01 JP JP2011552406A patent/JP2012519201A/ja active Pending
- 2010-03-01 MY MYPI2011004105A patent/MY162484A/en unknown
- 2010-03-01 AU AU2010220396A patent/AU2010220396B2/en not_active Ceased
- 2010-03-01 AR ARP100100600A patent/AR076070A1/es not_active Application Discontinuation
- 2010-03-01 CN CN2010800106646A patent/CN102341111A/zh active Pending
- 2010-03-01 WO PCT/EP2010/052551 patent/WO2010100112A1/en not_active Ceased
- 2010-03-01 PE PE2011001569A patent/PE20120327A1/es not_active Application Discontinuation
- 2010-03-01 US US13/202,586 patent/US20120052135A1/en not_active Abandoned
- 2010-03-01 RU RU2011140017/15A patent/RU2527682C2/ru not_active IP Right Cessation
- 2010-03-01 KR KR20117023162A patent/KR101497003B1/ko not_active Expired - Fee Related
- 2010-03-01 SG SG2011062239A patent/SG173887A1/en unknown
- 2010-03-01 TW TW099105799A patent/TWI454267B/zh not_active IP Right Cessation
-
2011
- 2011-08-08 IL IL214509A patent/IL214509A0/en unknown
- 2011-08-26 ZA ZA2011/06305A patent/ZA201106305B/en unknown
- 2011-09-01 CL CL2011002130A patent/CL2011002130A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG173887A1 (en) | 2011-10-28 |
| KR101497003B1 (ko) | 2015-02-27 |
| EP2403506A1 (en) | 2012-01-11 |
| TWI454267B (zh) | 2014-10-01 |
| US20120052135A1 (en) | 2012-03-01 |
| WO2010100112A1 (en) | 2010-09-10 |
| JP2012519201A (ja) | 2012-08-23 |
| NZ594730A (en) | 2013-06-28 |
| CL2011002130A1 (es) | 2012-03-23 |
| ZA201106305B (en) | 2012-05-30 |
| RU2527682C2 (ru) | 2014-09-10 |
| MY162484A (en) | 2017-06-15 |
| TW201034677A (en) | 2010-10-01 |
| PE20120327A1 (es) | 2012-04-11 |
| BRPI1009110A2 (pt) | 2019-09-24 |
| IL214509A0 (en) | 2011-09-27 |
| CA2753364A1 (en) | 2010-09-10 |
| CN102341111A (zh) | 2012-02-01 |
| AU2010220396B2 (en) | 2013-10-17 |
| RU2011140017A (ru) | 2013-04-10 |
| MX2011009144A (es) | 2011-09-15 |
| KR20110128329A (ko) | 2011-11-29 |
| AU2010220396A1 (en) | 2011-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076070A1 (es) | Absorbente de fosfato para el tratamiento de la hiperfosfatemia | |
| ES2397657T3 (es) | Preparación de combinación para mejorar la calidad del esperma | |
| JP2012519201A5 (es) | ||
| RU2600440C3 (ru) | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты | |
| EA201490477A1 (ru) | Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| JP6401317B2 (ja) | がんを治療するためのシステム、方法、および製剤 | |
| BRPI0910341A2 (pt) | dispositivo para conservação, preparação espontanea e administração de um principio ativo | |
| BRPI0814536B8 (pt) | inalador para pó | |
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| WO2012117257A8 (en) | Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer | |
| FI3511004T3 (fi) | Yhdistelmävalmisteita syövän hoitoon | |
| JP2009542623A5 (es) | ||
| ECSP088348A (es) | Composiciones de suplemento de hierro con tolerancia mejorada | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| PT2389070E (pt) | Formulações desintegráveis de carbonato de lantânio | |
| UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
| JP2013525422A5 (es) | ||
| RU2012131959A (ru) | Способ лечения остеоартрита | |
| AU2019200353A1 (en) | Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof | |
| ECSP077843A (es) | Tratamiento o prevención del prurito | |
| PE20130308A1 (es) | Metodos para tratar infecciones bacterianas recurrentes | |
| RU2015111491A (ru) | Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира | |
| TR201004720T1 (tr) | Majör depresif bozukluğun tedavisi için o-desmetil venlafaksin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |